Cardiac Prosthetic Devices Market Size & Share, by End user (Hospitals & Cardiac Centers, Ambulatory Surgical Centers, Specialty Clinics); Material; Product Type; Procedure; Application - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Cardiac Prosthetic Devices Market - Regional Analysis

North America Market Insights

The North America cardiac prosthetic devices market is projected to account for the highest share of 40.5% by the end of 2035. The growth in the region is effectively attributed to the advanced healthcare infrastructure and a prominent adoption of premium-priced innovations. For instance, in April 2025 University of Illinois reported that Professor Cunjiang Yu has developed a self-adhesive rubbery bio-optoelectronic stimulator, which is designed to help patients with cardiovascular diseases such as arrhythmia, hence suitable for standard market growth.

The U.S. is the dominating player in the cardiac prosthetic devices market, which is remarkably fueled by the Medicare expansion and accelerating approvals. The country hosts a substantial number of key players implementing tactical strategies to secure their global positions.  Besides, the cardiac procedural costs are also significantly rising, wherein the study published by AHA in February 2024 stated that the mean cost per discharge is highest for peripheral vascular disease at USD 33,700 and ventricular tachycardia/fibrillation at USD 32,500. Hence, these costs highlight the economic potential of cardiovascular disease in the U.S. healthcare system.

Canada is steadily consolidating its position in the cardiac prosthetic devices market, fueled by public healthcare expenditures. For instance, the Standing Committee on Finance 2023 Pre-budget consultation revealed that the country’s federal government has allocated a total of USD 700,000 per year over 5 years, which totaled to a substantial 3.5 million, to the Canadian Cardiovascular Society. It also stated that this funding aims to support initiatives that ensure heart failure patients receive optimal, standardized care across the country.

Key U.S. Cardiovascular Disease Prevention Programs (2021-2023)

Source: CDC

APAC Market Insights

The Asia Pacific market is poised to witness the fastest growth during the analyzed timeframe. The growth in the region is effectively facilitated by the rising burden of cardiovascular diseases, expanding medical tourism, and government-backed healthcare modernization.  Besides the presence of government subsidies, domestic manufacturing units and exclusive innovations readily drive business in this sector. Also, there is an amplified adoption of robotic surgery and affordable cardiovascular prosthetic devices, leading the way to utmost success.

China is the global leader in the market, successfully backed by the government healthcare policies and strong manufacturing capabilities. Besides domestic firms, which are continuously putting efforts to enhance R&D, international firms continue to maintain a strong presence in the market. In March 2025, MicroPort CRM Shanghai notified that it launched the localized TEN pacemaker family in the country, which features six models across single- and dual-chamber categories with advanced technologies such as AutoMRI for safe MRI scans and SAM for monitoring sleep breathing patterns and arrhythmias.

The cardiac prosthetic devices market in India is vigorously growing, owing to the presence of government-backed initiatives, increasing adoption in healthcare facilities, and domestic manufacturing capabilities.  In August 2024, Apollo Hospitals Chennai reported that it performed the country’s first-ever dual heart valve repair using Mitral and Tricuspid Transcatheter Edge-to-Edge Repair on a high-risk 59-year-old heart failure patient. It also stated that the procedure offers a less invasive alternative to traditional surgery, providing new hope for patients with severe valve issues, thereby strengthening the country’s position in this field.

Cardiac Prosthetic Devices Implantation Statistics (2022)

Source: APHRS

Europe Market Insights

Europe also stands at the forefront of growth in the cardiac prosthetic devices market, which is effectively fueled by the strong research ecosystem and medical device regulations. For instance, in July 2025, CARMAT reported that it had received the Medical Device Regulation CE marking for its Aeson artificial heart, which is designed to provide a therapeutic alternative for people with advanced biventricular heart failure. Furthermore, countries such as Germany, France, and the UK are also facilitating continued revenue in the region’s market.

Germany is predicted to grow remarkably in the cardiac prosthetic devices market over the forecasted years, backed by its well-established healthcare infrastructure and sophisticated medical technology. The country also hosts numerous leading healthcare facilities, which are capable of performing complex surgeries requiring cardiac prosthetics. In April 2022, TRiCares announced the successful first-in-human implantation of its Topaz transfemoral tricuspid heart valve replacement system in the country, which enables a minimally invasive treatment option for severe tricuspid regurgitation patients who are high-risk for open-heart surgery.

The U.K. is maintaining a strong position in the market owing to the increasing awareness regarding heart valve disease and the rising use of minimally invasive procedures.  For instance, in December 2024, the country’s government awarded a total of £80 million to support 100 innovative research projects across the country, including developments in prosthetics and healthcare, hence enhancing access and innovation in Germany’s cardiac care.